Table 3.
Demographics of patients treated with SP (n=32)
| Characteristic | n (%) |
|---|---|
| Median age (range), years | 35 (16–39) |
| Sex | |
| Male | 13 (40.6) |
| Female | 19 (59.4) |
| Disease status | |
| Unresectable | 25 (78.1) |
| Recurrent | 7 (21.9) |
| ECOG performance status | |
| 0 | 27 (84.4) |
| 1 | 4 (12.5) |
| 2 | 1 (3.1) |
| Histological appearance | |
| Intestinal-type | 1 (3.1) |
| Diffuse-type | 31 (96.9) |
| Macroscopic appearance | |
| Type 2 | 2 (6.3) |
| Type 3 | 10 (31.2) |
| Type 4 | 16 (50.0) |
| Others/unknown | 4 (12.5) |
| Primary tumor in place | |
| Yes | 17 (53.1) |
| No | 15 (46.9) |
| Number of metastatic sites | |
| 2> | 20 (62.5) |
| ≥2 | 12 (37.5) |
| Adjuvant chemotherapy | |
| Yes | 4 (12.5) |
| No | 28 (87.5) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; SP, S-1 plus cisplatin.